Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CAPR
CAPRICOR THERAPEUTICS, INC.
NASDAQ
$9.59
▼ DOWN 4.67% (-0.47)

KEY STATISTICS

Market Cap$551.53 M
52w High$40.37
52w Low$2.96
Dividend Yield—
Frequency—
P/E-3.91
Volume5.16M
Shares Out.57.51M

COMPANY

LEADERSHIP

Linda Marbán
CHIEF EXECUTIVE
Linda Marbán

COMPENSATION 2026

Salary$300,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$10,645
Total$3,521,565

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 13, 2007
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
231

PRICE TARGET

Target High$7.00
Target Low$3.50
Target Median$7.00
Target Consensus$5.83

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$41.71M
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2019-06-05Reverse1:10
2013-11-21Reverse1:50
2007-02-13Reverse1:10

PRICE

$9.59 ▼ DOWN 4.67% (−$0.47)
OVERLAYS
$9.60$9.80$10.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM9.59

About Capricor Therapeutics, Inc.

https://www.capricor.com ↗

Capricor Therapeutics is a San Diego-based biotech developing cell and exosome therapies, including CAP-1002 for Duchenne muscular dystrophy and COVID-19 cytokine storm, with ongoing clinical trials and preclinical programs.

INDUSTRY

Biotechnology

A PRODUCT CAPRICOR THERAPEUTICS, INC. IS KNOWN FOR

Deramiocel
Deramiocel

Deramiocel, Capricor's lead allogeneic CDC therapy in late-stage trials, targets cardiac and skeletal muscle issues in Duchenne muscular dystrophy and has received FDA Orphan Drug and RMAT designations.

COMPETITORS

COMPETITOR
EWTX COMPARE
PTCT COMPARE
SRPT COMPARE
VRTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
96
LISTED HERE
17
RANKED BY POSITION SIZE
XBI
0.20% · 2.3M
VTS.AX
0.00% · 1.7M
IWM
0.01% · 1.4M
LABU
0.13% · 84.2K
FSCC
0.18% · 78.5K
XRSG.L
0.02% · 49.2K
RSSL
0.02% · 25.5K
FHLC
0.01% · 22.1K
BBSC
0.02% · 15.0K
BBC
0.23% · 12.2K
URTY
0.01% · 2.2K
RFLR
0.02% · 2.0K
WCEO
0.08% · 1.1K
PWS
0.04% · 1.0K
USUE.DE
0.00% · 185
RESM
0.02% · 101
SC0K.DE
0.02% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
42.11%
HOLDERS
224
TOP 12 OF 224 · RANKED BY POSITION SIZE
Suvretta Capital Management, LLC
3.8M sh · $116.09M
Blackrock, Inc.
3.4M sh · $104.02M
Tang Capital Management LLC
3.4M sh · $103.36M
Vanguard Group Inc
2.6M sh · $73.94M
State Street Corp
2.2M sh · $66.33M
Point72 Asset Management, L.P.
1.8M sh · $53.1M
Blackrock Inc.
1.6M sh · $7.77M
Ra Capital Management, L.P.
1.5M sh · $45.84M
Geode Capital Management, LLC
1.1M sh · $34M
Fmr LLC
922.6K sh · $26.63M
Goldman Sachs Group Inc
912.0K sh · $27.72M
Citadel Advisors LLC
902.0K sh · $26.03M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: EVP, GENERAL COUNSEL
Krasney Karen
Sale · 24.1K shares
2026-06-25
★
OFFICER: EVP, GENERAL COUNSEL
Krasney Karen
Purchase · 24.1K shares
2026-06-25
★
OFFICER: CHIEF FINANCIAL OFFICER
Bergmann Anthony
Sale · 24.1K shares
2026-06-25
★
OFFICER: CHIEF FINANCIAL OFFICER
Bergmann Anthony
Purchase · 24.1K shares
2026-06-25

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
NEUTRAL 2
OVERWEIGHT 1
HOLD 1
OUTPERFORM 1
8 GRADES IN THE LAST 12 MONTHS
Cantor Fitzgerald OVERWEIGHT Jones Trading HOLD Piper Sandler NEUTRAL HC Wainwright & Co. NEUTRAL B. Riley Securities BUY Oppenheimer OUTPERFORM Maxim Group BUY Roth Capital BUY

SECTORS PEERS

PEERPRICE
ACHV$8.10COMPARE
ALLO$2.02COMPARE
CABA$3.12COMPARE
EDIT$3.16COMPARE
ARCT$15.19COMPARE
LXEO$4.86COMPARE
VNDA$5.29COMPARE
TRDA$7.00COMPARE